LGNDLigand Pharmaceuticals Incorporated
Is it safe?
Strong, no red flags: a safe balance sheet and comfortable debt (AA).
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$16.1M, 90 days to Oct 8, 2026), selling is often routine.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -77% · now 5% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can LGND take a bad year?
Ligand Pharmaceuticals Incorporated holds $231M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 7.96
Altman Z-score · safe zone, above 3
- Interest cover
- 15.3×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $1.13B
- Cash and short-term investments
- $1.36B
- Net cash
- $231M
- EBITDA, trailing twelve months
- $128M
- Operating profit, trailing twelve months
- $95M
- Debt / equity
- 1.16×
- Total debt / EBITDA
- 8.83×
- Annualised volatilitytwo years of daily moves
- 38%
- Worst drawdown on file
- −77%
- Below its 52-week high
- 4.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.